Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novel Full-Range Lentivirus Platform from Widely Accessible Core Facility

Published: Wednesday, August 14, 2013
Last Updated: Wednesday, August 14, 2013
Bookmark and Share
Working with lentivirus experiences new heights with latest launches by SIRION Biotech.

SIRION Biotech has announced its novel lentivirus portfolio for the most sophisticated in vitro applications. Besides its (1) non-toxic transduction enhancer coined LentiBOOST™ , SIRION Biotech offers (2) premade lentivirus vectors and (3) custom services.

The latter allows for all possible modifications and applications ranging from complex and multiple genes expression to TET- inducible all-in-one vectors; lentivirus particles can be ordered directly or as basis for an entire cell line production. The finished cell lines come virus free and ready-to-use.

Genetic modification is a prerequisite for today's target research and cell based assay screening for compound development.

Viral vectors work both in vitro and in vivo, are versatile and warrant high gene delivery rates: The viruses' own infection machinery is being used to transport genetic material into the host cells.

Several viral vector platforms are in use: lentivirus lends itself to stable gene modifications as opposed to transient modifications like with adenovirus (AV) and adeno-associated virus (AAV).

Specialized service providers like SIRION Biotech are able to provide custom lentivirus and the resulting stable cell pools within a matter of weeks, premade lentiviral particles can be shipped literally over night.

The availability of such focused services allows for faster and more reliable research.

Viral vector technologies are applicable from drug discovery to food sciences and cosmetics developments.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!